Search, analyze & compare

My selected companies

Adjust valuation method
WatchlistNameTickerP/EP/SP/BEV/EbitdaROEROICRSISMA200DCFVolumeClosing price
-
Aclaris Therapeutics IncACRS-3.957.241.63-1.68-25.83%-16.04%62.68$2.63$8.695,119$3.25

Detail of Aclaris Therapeutics Inc

 
CEO
Dr. Neal S. Walker D.O., M.D.
Employees
86
Industry
Diagnostics & Research
Sector
Healthcare
Market cap
$232M

Company details

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Revenue
Cost of goods
Gross profit
OE
R&D
G&A
OI
OIE
PI
NI
Revenue (Rev)
$32.02M
Cost of goods (CoG)
-$18.37M
Gross profit (GP)
$13.65M
Operating expense (OE)
-$96.03M
Research and development (R&D)
-$69.13M
General and administrative (G&A)
-$26.90M
Operating income (OI)
-$82.38M
Other income expense (OIE)
-$23.33M
Pretax income (PI)
-$59.05M
Net income (NI)
-$58.68M
Aclaris Therapeutics Inc
ACRS • XNGS • US
$3.25
+2.25 (222.77%)
Stock vs Industry average
  • Industry average

Negative values are hidden from the graph.
Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
-$0.82
Margin profit
-136.65%
52 week low
$0.924
52 week high
$4.88
50-day simple moving average
$3.16
200-day simple moving average
$2.63
Percent held by insiders
3.65%
Percent held by institutions
90.21%
Dividend yield
0.00%

Change of shares

Cash vs Debt

Insider Trading

Comparison of selected companies

 
%
Price change
ACRS +204.67%
eps change
ACRS 0.00%